Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 676 results for diabetes

  1. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

    Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

  2. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date:  26 August 2026

  3. Leg ulcer infection: antimicrobial prescribing (NG152)

    This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

  4. Forward view - our priority topics

    Our forward view highlights the topics we will prioritise in the coming year.

  5. How can fetuses at risk of intrauterine death be identified in women with diabetes?

    How can fetuses at risk of intrauterine death be identified in women with diabetes? Any explanatory notes(if applicable) Unexpected...

  6. Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

    Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults.

  7. Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)

    Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.

  8. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

  9. Smoking: smoking status of people with long-term conditions (IND156)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126

  10. Kidney conditions: CKD - ACEi and ARB (IND263)

    This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247

  11. Diabetes: statins for secondary prevention of CVD

    This guidance has been updated and replaced by NICE indicator 276.

  12. Metreleptin for treating lipodystrophy (HST14)

    Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.

  13. Are there effective long-term pharmacological interventions to prevent the onset of type 2 diabetes that can be recommended postnatally for women who have been diagnosed with gestational diabetes?

    prevent the onset of type 2 diabetes that can be recommended postnatally for women who have been diagnosed with gestational...

  14. Glycated haemoglobin testing:- Does optimisation of HbA1c in people with poorly controlled diabetes improve surgical outcomes?

    poorly controlled diabetes improve surgical outcomes? Any explanatory notes(if applicable) Why this is important:- Diabetes...

  15. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests